СОВРЕМЕННЫЙ ВЫБОР ДЛЯ ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ: ВОЗМОЖНОСТИ НОВЫХ АНТАГОНИСТОВ КАЛЬЦИЯ III ПОКОЛЕНИЯ
https://doi.org/10.20996/1819-6446-2015-11-5-535-542
Аннотация
Рассматриваются особенности и возможности применения в кардиологической практике антагониста кальция лерканидипина. Использование лерканидипина в лечении пациентов с артериальной гипертензией подкреплено обширными доказательными данными. Также рассматривается применение лерканидипина у отдельных категорий больных, в том числе – в составе комбинированной терапии. Отдельно обсуждается безопасность применения лерканидипина у кардиологических пациентов.
Об авторах
Е. И. Емелина
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова 117997, Москва, ул. Островитянова, 1
Россия
Россия
к.м.н., доцент кафедры госпитальной терапии No2 РНИМУ им. Н.И. Пирогова
Г. Е. Гендлин
Российский национальный исследовательский медицинский университет им. Н.И. Пирогова 117997, Москва, ул. Островитянова, 1
Россия
Россия
д.м.н., профессор кафедры госпитальной терапии No2 РНИМУ им. Н.И. Пирогова
Список литературы
1. National guidelines on the diagnosis and treatment of hypertension. Sistemnye Gipertenzii 2010; 3: 5-26. In Russian (Национальные рекомендации по диагностике и лечению артериальной гипертензии. Системные Гипертензии 2010; 3: 5-26).
2. Mancia G., Fagard R., Narkiewicz K. et al.; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281-357.
3. Mancia G., Laurent S., Agabiti-Rosei E. et al.; European Society of Hypertension. Re-appraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27(11): 2121-58.
4. Robles N.R., Canelada J.A., Iglesias M. et al. Evaluation of lercanidipine in the general practice setting. An Med Interna 2003; 20(6): 282-6.
5. McClellan K., Jarvis B. Lercanidipine. A review of its use in Hypertension. Drugs 2000; 60 (5): 1123-40.
6. Taddei S., Virdis A., Ghiadoni L. et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarisation in essential hypertension. Hypertension 2003; 41 (4): 950-5.
7. Preobrazenskii DV, Sidorenko BA, Dedov IS et al. Lercanidipine a new calcium antagonist of the third generation: clinical pharmacology and experience of use in the treatment of hypertension. Russkiy Meditsinskiy Zhurnal 2006; 20: 1411-8. In Russian (Преображенский Д.В., Сидоренко Б.А., Дедова И.С. и др. Лерканидипин – новый антагонист кальция третьего поколения: клиническая фармакология и опыт применения при лечении артериальной гипертензии. Русский Медицинский Журнал 2006; 20: 1411-8).
8. Burnier M., Gasser U.E. Efficacy and tolerability of lercaniclipine in patients with hypertension: results of a Phase IV study in general practice. Expert Opin Pharmacother 2007; 8(14): 2215-23.
9. Herbette L., Vecchiarelli M., Sartani A. et al. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties. Blood Press 1998; Suppl 2: 10-7.
10. Notarbartolo A., Rengo F., Scafidi V. et al. Long-term effects of lercanidipine on the lipoprotein and apolipopprotein profile of patients with mild-to-moderate essential hypertension. Curr Ther Res 1999; 60: 228-36.
11. Schwinger R.H.G., Schmidt-Mertens A. The new lipophilic calcium channel blocker lercanidipine combines high antihypertensive efficacy with low side effects. Dtsch Med Wochenschr 2002; 127 Suppl 1: s13.
12. Zanchetti A., Bond M.G., Hennig M. et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-7.
13. Fagard R.H., Celis H., Thijs L., Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009; 54: 1084-91.
14. Bang L., Chapman T., Goa K. Lercanidipine – a review of its efficacy in management of hypertension. Drugs 2003; 22: 2449-72.
15. NICE. Hypertension: clinical management of primary hypertension in adults (Clinical guidelines, CG127 Issued: August 2011). Available at: http://guidance.nice.org.uk/CG127. Accessed by 20.10.2015.
16. Luque M., Ruilope L.M., Tamargo J. et al. Drug surveillance study in patients with mild to moderate hypertension treated with lercanidipine: the ZANYTEN study. Am J Hypertens 2004; 20 Suppl 4: S163.
17. Ninci M.A., Magliocca R., Malliani A. Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study. J Cardiovasc Pharmacol 1997; 29: S40-4.
18. Policicchio D., Magliocca R., Malliani A. Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow release nifedipine. J Cardiovasc Pharmacol 1997; 29: S31-5.
19. Romito R., Pansini M., Perticone F. et al. Comparative effect of lercanidipine, felodipine and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: The Lercanidipine in Adults (LEAD) Study. J Clin Hyprtens 2003; 5 (4): 249-53.
20. Cherubini A., Fabris F., Ferrari E. et al. Comparative effects of lercanidipine, lacidipine and nifidepine GITS on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003 ;3: 203-12.
21. Zanchetti A. Emerging data on calcium-channel blockers: the COHORT study. Clin Cardiol 2003; 26 (Suppl 2): II 17-20.
22. Poncelet P., Ribstein J., Goullard L. et al. Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study. Ann Cardiol Angeiol (Paris) 2004; 53(3):123-30.
23. Leonetti G., Magnani B., Pessina A.C. et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15: 932-40.
24. Millar-Craig M., Shaffu B., Greenough A. et al. Lercanidipine vs lacidipine in isolated systolic hypertension. J Hum Hypertens 2003; 17: 799-806.
25. Seravalle G., Stella M.L., Foglia G. et al. Temporal profile of antihypertensive drug-induced regression of cardiac and vascular structural alterations in hypertension. J Hypertens 2002; 20: S190.
26. Barbagallo M., Barbagallo S.G. Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging (Milano) 2000; 12: 375-9.
27. Rengo F., Romis L. Activity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hypertension. J Cardiovasc Pharmacol 1997; 29:S54-8.
28. Fogari R., Mugellini A., Zoppi A. et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003; 16 (7): 596-9.
29. Mackenzie I.S., McEniery C.M., Dhakam Z. et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009; 54: 409-13.
30. Borghi C., Prandin M.G., Dormi A. et al. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press Suppl 2003; 1: 14-21.
31. Barrios V., Navarro A., Esteras A. et al.; Investigators of ELYPSE Study (Eficacia de Lercanidipino y su Perfil de Seguridad). Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad. Blood Press 2002; 11(2):95-100.
32. Viviani G.L. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J Cardiovasc Pharmacol 2002; 40: 133-9.
33. Marx A., Lichtenthal A., Milbredt C. et al. Effect of anthypertensive therapy with a new third generation calcium antagonist lercanidipine on patients with concomitant diseases. J Hypertens 2004; 22 Suppl 2: S236.
34. Barrios V., Calderon A., Navarro A. et al. Lercanidipine is an effective and well tolerated drug in essential hypertension, independently of the cardiovascular risk. The Laura study. J Hypertens 2004; 22 Suppl 2: S235
35. Acanfora D., Trojano L., Gheorghiade M. et al. A randomized, double-blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina: effects on myocardial ischemia and heart rate variability. Am J Ther 2002; 9 (5): 444-53.
36. Taddei S., Virdis A., Ghiadoni L. et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarisation in essential hypertension. Hypertension 2003; 41 (4): 950-5.
37. Weir M.R. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich) 2003; 5: 330-5.
38. Bellosta S., Bernini F. Lipophilic calcium antagonists in antiatherosclerotic therapy. Curr Atheroscler Rep 2000; 2: 76-81.
39. Leonetti G. The safety profile of antihypertensive drugs as the key factor for the achievement of blood pressure control: current experience with lercanidipine. High Blood Press 1999; 8: 92-101.
40. Zanchetti A. Calcium channel blockers in hypertension. Chapt. 22. In: Black H.R., Elliott W.J., eds. Hypertension: a Companion to Braunwald’s Heart Disease. Philadelphia; Saunders: 2012: 204-18.
41. Fogari R., Mugellini A., Zoppi A. et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003; 16 (7): 596-9.
42. Notarbartolo A., Rengo F., Scafidi V. et al. Long-term effects of lercanidipine on the lipoprotein and aholipoprotein profile of patients with mild to moderate essential hypertension. Curr Ther Res 1999; 60 (4): 228-36.
43. Viviani G.L. Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension. J Cardiovasc Pharmacol 2002; 40: 133-9.
44. Sabbatini M., Leonardi A., Testa R. et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35: 775-9.
45. Dalla Vestra M., Pozza G., Mosca A. et al. Effect of lercanidpine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (Diabete, Ipertensione, Albuminuria, Lercanidipina). Diabetes Nutr Metab 2004; 17: 259-66.
46. Burnier M. Renal protection with calcium antagonists: the role of lercanidipine. Curr Med Res Opin 2013; 29(12): 1727-35.
47. Luque M., Ruilope L.M., Tamargo J. et al. Drug surveillance study in patients with mild to moderate hypertension treated with lercanidipine: the ZANYTEN study. Am J Hypertens 2004; 20: Suppl 4: S163
48. Aronow W.S., Fleg J.L., Pepine C.J. et al.; ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2011; 123(21): 2434-506.
49. Taddei S., Virdis A., Ghiadoni L. et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 2003; 41: 950-5.
50. Hollenberg N.K. Observations on the safety of lercanidipine: adverse event data from placebo-controlled trials. Am J Hypertens 2002; 15: 58A-59A.
51. Robles N.R., Pastor L., Manjon M. et al. Lercanidipine in diabetic patients with renal failure // Nefrologia. 2004. V. 24. P. 338-343.
52. Robles N.R., Romero B., Garcia de Vinuesa E. et al. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail 2010; 32(2): 192-7.
53. Mallion J.M., Allaert F.A., Scart-Gres C. et al. Variations in the frequency of lower limb oedema in patients recieving lercanidipine in adjunction to their antihypertensive treatment. J Hypertens 2004; 22 Suppl 2: S269
54. Cicero A.F.G., Gerocarni B., Rosticci M., Borghi C. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens 2012; 34(2): 113-7.
55. Guillen V.F.G., Abellan J., Llisterri J.L. et al. Efficacy and safety of lercanidipine in combination with enalapril in HBP. Preliminary results of ZANYCONTROL study group. Am J Hypertens 2003; 16: 115A.
56. Borghi C. Lercanidipine in hypertension. Vasc Health Risk Manag 2005; 1(3): 173-82.
Рецензия
Для цитирования:
Емелина Е.И., Гендлин Г.Е. СОВРЕМЕННЫЙ ВЫБОР ДЛЯ ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ: ВОЗМОЖНОСТИ НОВЫХ АНТАГОНИСТОВ КАЛЬЦИЯ III ПОКОЛЕНИЯ. Рациональная Фармакотерапия в Кардиологии. 2015;11(5):535-542. https://doi.org/10.20996/1819-6446-2015-11-5-535-542
For citation:
Emelina E.I., Gendlin G.E. A modern choice for patients with hypertension: the possibility of new calcium antagonist of III generation. Rational Pharmacotherapy in Cardiology. 2015;11(5):535-542. (In Russ.) https://doi.org/10.20996/1819-6446-2015-11-5-535-542
Просмотров:
951
Послать статью по эл. почте 